Estrogen‐Induced LncRNA, LINC02568, Promotes Estrogen Receptor‐Positive Breast Cancer Development and Drug Resistance Through Both In Trans and In Cis Mechanisms
Advanced Science · 2023
DOI: 10.1002/advs.202206663 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2023. Verfasst von Xue Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen University, Xiang'an South Road, Xiamen, 361102, Fujian, C…. Hauptthemen laut MEDLINE: Breast Neoplasms, RNA, Long Noncoding. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Natural Science Foundation of Fujian Province of China.
Abstract (Originalsprache)
Endocrine therapy is the frontline treatment for estrogen receptor (ER) positive breast cancer patients. However, the primary and acquired resistance to endocrine therapy drugs remain as a major challenge in the clinic. Here, this work identifies an estrogen‐induced lncRNA, LINC02568, which is highly expressed in ER‐positive breast cancer and functional important in cell growth in vitro and tumorigenesis in vivo as well as endocrine therapy drug resistance. Mechanically, this work demonstrates that LINC02568 regulates estrogen/ER α ‐induced gene transcriptional activation in trans by stabilizing ESR1 mRNA through sponging miR‐1233‐5p in the cytoplasm. Meanwhile, LINC02568 contributes to tumor‐specific pH homeostasis by regulating carbonic anhydrase CA12 in cis in the nucleus. The dual functions of LINC02568 together contribute to breast cancer cell growth and tumorigenesis as well as endocrine therapy drug resistance. Antisense oligonucleotides (ASO) targeting LINC02568 significantly inhibits ER‐positive breast cancer cell growth in vitro and tumorigenesis in vivo. Furthermore, combination treatment with ASO targeting LINC02568 and endocrine therapy drugs or CA12 inhibitor U‐104 exhibits synergistic effects on tumor growth. Taken together, the findings reveal the dual mechanisms of LINC02568 in regulating ER α signaling and pH homeostasis in ER‐positive breast cancer, and indicated that targeting LINC02568 might represent a potential therapeutic avenue in the clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen University, Xiang'an South Road, Xiamen, 361102, Fujian, China.
- Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiang'an South Road, Xiamen, 361102, Fujian, China.
- Xiang An Biomedicine Laboratory, School of Pharmaceutical Sciences, Xiamen University, Xiang'an South Road, Xiamen, 361102, Fujian, China.
- Department of Anus and Bowels, Affiliated Nanhua Hospital, University of South China, Dongfeng South Road, Hengyang, 421002, Hunan, China.
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiang'an South Road, Xiamen, 361102, Fujian,…
- Department of Pathology, The Second Affiliated Hospital, Shantou University Medical College, Dongxia North Road, Shantou, 515041, Guangdong, China.
ORCID-Profile: Wen Liu
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Natural Science Foundation of Fujian Province of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Chen, X., Ding, J. C., Hu, G. S., Shu, X. Y., Liu, Y., Du, J., Wen, Z. J., Liu, J. Y., Huang, H. H., Tang, G. H., & Liu, W. (2023). Estrogen‐Induced LncRNA, LINC02568, Promotes Estrogen Receptor‐Positive Breast Cancer Development and Drug Resistance Through Both In Trans and In Cis Mechanisms. Advanced Science. https://doi.org/10.1002/advs.202206663
Vancouver
Chen X, Ding JC, Hu GS, Shu XY, Liu Y, Du J, et al. Estrogen‐Induced LncRNA, LINC02568, Promotes Estrogen Receptor‐Positive Breast Cancer Development and Drug Resistance Through Both In Trans and In Cis Mechanisms. Advanced Science. 2023. doi:10.1002/advs.202206663
BibTeX
@article{Chen2023,
author = {Chen, Xue and Ding, Jian-Cheng and Hu, Guo-Sheng and Shu, Xing-Yi and Liu, Yan and Du, Jun and Wen, Zi-Jing and Liu, Jun-Yi and Huang, Hai-Hua and Tang, Guo-Hui and Liu, Wen},
title = {Estrogen‐Induced LncRNA, LINC02568, Promotes Estrogen Receptor‐Positive Breast Cancer Development and Drug Resistance Through Both In Trans and In Cis Mechanisms},
journal = {Advanced Science},
year = {2023},
doi = {10.1002/advs.202206663}
}
EUVIMED